Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6721 to 6735 of 8314 results

  1. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Medtech innovation briefing
    Published
    15 June 2018

  2. Utrasound-guided foam sclerotherapy for varicose veins (IPG314)

    This guidance has been updated and replaced by NICE interventional procedure guidance 440.

    Interventional procedures guidance
    Published
    23 August 2009

  3. Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG309)

    This guidance has been updated and replaced by NICE interventional procedure guidance 649.

    Interventional procedures guidance
    Published
    26 August 2009

  4. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Evidence summary
    Published
    12 May 2021

  5. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE interventional procedures guidance 793.

    Interventional procedures guidance
    Published
    22 June 2016

  6. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Technology appraisal guidance
    Published
    23 July 2001

  7. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Evidence summary
    Published
    24 June 2014

  8. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789. 

    Interventional procedures guidance
    Published
    24 February 2010

  9. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  10. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Technology appraisal guidance
    Published
    7 August 2019

  11. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Technology appraisal guidance
    Published
    15 May 2019

  12. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  13. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Technology appraisal guidance
    Published
    12 June 2024

  14. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Technology appraisal guidance
    Published
    21 March 2018

  15. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Technology appraisal guidance
    Published
    27 March 2002